MedTrace Logo

Pilot Trial of Colchicine for Graft Failure in CABG

NCT06802926 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-01-02

No results posted yet for this study

Summary

The goal of this pilot trial is to to evaluate the preliminary effect of oral colchicine therapy on graft outcomes in patients underwent primary isolated CABG.

The main questions it aims to answer is:

1. Whether the oral colchicine therapy may reduce the failure outcome of grafts after CABG.
2. Whether it is feasible to construct a muticenter powered trial to test the superiority hypothesis.

Researchers will compare colchicine to none to see if colchicine works.

Participants will

1. Take oral colchicine (0.5mg daily) therapy for 12 months after CABG.
2. Clinical follow-up at Month 1, 6, and 12 after CABG.
3. Protocol-driven CCTA at Week 1 and Month 12 after CABG.

Conditions

  • CABG
  • Graft Failure
  • Colchicine

Interventions

DRUG

Colchicine

Oral Colchicine 0.5mg qd for 1 year

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Qiang Zhao, MD · Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China

  • Yunpeng Zhu, MD · Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-29
Primary Completion
2027-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06802926 on ClinicalTrials.gov